MA26152A1 - Methode de traitement des maladies ou des cas de demyelinisation. - Google Patents

Methode de traitement des maladies ou des cas de demyelinisation.

Info

Publication number: MA26152A1
Authority: MA; Morocco
Prior art keywords: demyelinization; diseases; cases; treatment
Prior art date: 2001-02-15

Application number

MA27235A

Other languages

English (en)

Inventor

Craig P Smith

Michel P Rathbone

Margaret Petty

David Rampe

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-15

Filing date

2003-07-11

Publication date

2004-07-01

2003-07-11 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2004-07-01 Publication of MA26152A1 publication Critical patent/MA26152A1/fr

Links

201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

MA27235A 2001-02-15 2003-07-11 Methode de traitement des maladies ou des cas de demyelinisation. MA26152A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26884601P	2001-02-15	2001-02-15
GBGB0119435.6A GB0119435D0 (en)	2001-02-15	2001-08-09	Method of treating of demyelinating diseases or conditions

Publications (1)

Publication Number	Publication Date
MA26152A1 true MA26152A1 (fr)	2004-07-01

Family

ID=23024747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27235A MA26152A1 (fr)	2001-02-15	2003-07-11	Methode de traitement des maladies ou des cas de demyelinisation.

Country Status (39)

Country	Link
US (10)	US6967210B2 (fr)
EP (1)	EP1368031A2 (fr)
JP (3)	JP2004518711A (fr)
KR (3)	KR100951540B1 (fr)
CN (2)	CN1529598A (fr)
AP (1)	AP1749A (fr)
AR (1)	AR035750A1 (fr)
AU (3)	AU2002247200B9 (fr)
BR (1)	BR0207272A (fr)
CA (1)	CA2438712A1 (fr)
CO (1)	CO5390085A1 (fr)
CR (1)	CR7023A (fr)
CZ (1)	CZ20032172A3 (fr)
EA (2)	EA012409B1 (fr)
EC (1)	ECSP024218A (fr)
EE (1)	EE200300363A (fr)
GB (1)	GB0119435D0 (fr)
HK (1)	HK1080361B (fr)
HR (1)	HRP20030652A2 (fr)
HU (1)	HUP0303203A3 (fr)
IL (2)	IL157341A0 (fr)
MA (1)	MA26152A1 (fr)
ME (1)	MEP21208A (fr)
MX (1)	MXPA03006110A (fr)
MY (1)	MY157745A (fr)
NO (1)	NO20033622L (fr)
NZ (4)	NZ544720A (fr)
OA (1)	OA12549A (fr)
PA (1)	PA8540101A1 (fr)
PE (1)	PE20040175A1 (fr)
PL (1)	PL363638A1 (fr)
SG (1)	SG134170A1 (fr)
SK (1)	SK10392003A3 (fr)
TR (4)	TR200800693T2 (fr)
TW (1)	TWI325319B (fr)
UA (2)	UA80394C2 (fr)
WO (1)	WO2002064126A2 (fr)
YU (1)	YU62903A (fr)
ZA (1)	ZA200306124B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions
ES2288641T3 (es) *	2002-12-20	2008-01-16	Dynogen Pharmaceuticals Inc.	Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
AU2004207010A1 (en) *	2003-01-30	2004-08-12	Dynogen Pharmaceuticals, Inc.	Methods of treating lower urinary tract disorders using sodium channel modulators
EP1721607A1 (fr) *	2003-03-21	2006-11-15	Dynogen Pharmaceuticals, Inc.	Méthodes de traitement de troubles des voies urinaires inférieures avec des modulateurs des muscles lisses et des modulateurs des canaux calciques de la sous-unité alpha-2-delta
GT200500063A (es) *	2004-04-01	2005-10-14		Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) *	2005-04-28	2005-06-22	Paradigm Therapeutics Ltd	Ion channel
FR2892021B1 (fr) *	2005-10-19	2008-01-04	Urogene	Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) *	2005-10-19	2008-01-04	Urogene Sa	Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) *	2006-06-16	2013-04-16	Landon C. G. Miller	Compositions and methods for regulating membrane potential
DE102008044844B4 (de) *	2008-08-28	2018-08-30	Siemens Healthcare Gmbh	Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) *	2010-03-26	2018-05-31	가부시키가이샤 한도오따이 에네루기 켄큐쇼	반도체 장치
WO2012009204A1 (fr) *	2010-07-15	2012-01-19	The Trustees Of Columbia University In The City Of New York	Procédés pour le diagnostic et le traitement de troubles commotionnels
US20130030025A1 (en) *	2011-01-28	2013-01-31	Wessel Thomas C	Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) *	2011-10-04	2017-07-21	艾可達醫療公司	使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
WO2019126643A1 (fr) *	2017-12-22	2019-06-27	Massachusetts Institute Of Technology	Compositions et méthodes de thérapie du syndrome de williams (sw)
WO2022159086A1 (fr) *	2021-01-20	2022-07-28	Rush University Medical Center	Traitement amélioré pour la leucodsytrophie à cellules globoïdes ou la maladie de krabbe

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE115143T1 (de) *	1987-04-24	1994-12-15	Hoechst Roussel Pharma	N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US4970218A (en) *	1987-04-24	1990-11-13	Hoechst-Roussel Pharmaceuticals Inc.	N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) *	1987-04-24	1989-11-14	Hoechst-Roussel Pharmaceuticals, Inc.	N-(pyridinyl)-1H-indol-1-amines
FI95466C (fi)	1989-08-02	1996-02-12	Hoechst Roussel Pharma	Menetelmä terapeuttisesti aktiivisten 2,3-dihydro-1-(pyridyyliamino)indolien valmistamiseksi
US5214038A (en) *	1991-04-15	1993-05-25	Hoechst-Roussel Pharmaceuticals Inc.	1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) *	1993-07-29	1995-02-02	Boehringer Ingelheim Kg	Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en)	1994-05-13	1995-10-17	Hoechst-Roussel Pharmaceuticals Inc.	Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en)	1994-11-08	1996-10-15	Muhlhauser; Mark A.	Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (fr)	1995-03-10	1996-09-11	Boehringer Mannheim Gmbh	Procédé de fabrication d'un agent thérapeutique pour la régénération d'oligodendrocytes
FR2754147B1 (fr)	1996-10-03	2000-02-04	Mbh Technologies Sa	Installation et procede pour le traitement de carcasses
DK1056754T3 (da) *	1998-01-29	2004-02-16	Bristol Myers Squibb Co	Phosphatderivater af diaryl-1,3,4-oxadiazolon
AU5483500A (en)	1999-07-09	2001-01-30	Ortho-Mcneil Pharmaceutical, Inc.	Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions

2001
- 2001-08-09 GB GBGB0119435.6A patent/GB0119435D0/en not_active Ceased
2002
- 2002-02-14 MX MXPA03006110A patent/MXPA03006110A/es active IP Right Grant
- 2002-02-14 CN CNA028048644A patent/CN1529598A/zh active Pending
- 2002-02-14 HR HR20030652A patent/HRP20030652A2/hr not_active Application Discontinuation
- 2002-02-14 EA EA200600896A patent/EA012409B1/ru not_active IP Right Cessation
- 2002-02-14 TR TR2008/00693T patent/TR200800693T2/xx unknown
- 2002-02-14 TR TR2008/00692T patent/TR200800692T2/xx unknown
- 2002-02-14 CA CA002438712A patent/CA2438712A1/fr not_active Abandoned
- 2002-02-14 EE EEP200300363A patent/EE200300363A/xx unknown
- 2002-02-14 NZ NZ544720A patent/NZ544720A/en unknown
- 2002-02-14 AP APAP/P/2003/002834A patent/AP1749A/en active
- 2002-02-14 HU HU0303203A patent/HUP0303203A3/hu unknown
- 2002-02-14 NZ NZ539159A patent/NZ539159A/en unknown
- 2002-02-14 SK SK1039-2003A patent/SK10392003A3/sk unknown
- 2002-02-14 TR TR2008/00691T patent/TR200800691T2/xx unknown
- 2002-02-14 BR BR0207272-6A patent/BR0207272A/pt not_active IP Right Cessation
- 2002-02-14 NZ NZ556697A patent/NZ556697A/en unknown
- 2002-02-14 TR TR2003/01330T patent/TR200301330T2/xx unknown
- 2002-02-14 JP JP2002563920A patent/JP2004518711A/ja not_active Ceased
- 2002-02-14 EA EA200300882A patent/EA011319B1/ru not_active IP Right Cessation
- 2002-02-14 US US10/076,191 patent/US6967210B2/en not_active Expired - Lifetime
- 2002-02-14 KR KR1020037010691A patent/KR100951540B1/ko not_active Expired - Fee Related
- 2002-02-14 PL PL02363638A patent/PL363638A1/xx not_active Application Discontinuation
- 2002-02-14 ME MEP-212/08A patent/MEP21208A/xx unknown
- 2002-02-14 AU AU2002247200A patent/AU2002247200B9/en not_active Ceased
- 2002-02-14 CN CNB2005100597348A patent/CN100522164C/zh not_active Expired - Fee Related
- 2002-02-14 WO PCT/US2002/005501 patent/WO2002064126A2/fr not_active Ceased
- 2002-02-14 KR KR1020087031855A patent/KR100951542B1/ko not_active Expired - Fee Related
- 2002-02-14 EP EP02714974A patent/EP1368031A2/fr not_active Withdrawn
- 2002-02-14 UA UA2003098376A patent/UA80394C2/uk unknown
- 2002-02-14 CZ CZ20032172A patent/CZ20032172A3/cs unknown
- 2002-02-14 KR KR1020087031854A patent/KR20090005254A/ko not_active Ceased
- 2002-02-14 NZ NZ527011A patent/NZ527011A/en unknown
- 2002-02-14 YU YU62903A patent/YU62903A/sh unknown
- 2002-02-14 IL IL15734102A patent/IL157341A0/xx unknown
- 2002-02-14 OA OA1200300199A patent/OA12549A/en unknown
- 2002-02-14 SG SG200505802-9A patent/SG134170A1/en unknown
- 2002-02-15 CO CO02013025A patent/CO5390085A1/es not_active Application Discontinuation
- 2002-02-15 AR ARP020100540A patent/AR035750A1/es unknown
- 2002-02-15 EC EC2002004218A patent/ECSP024218A/es unknown
- 2002-02-15 MY MYPI20020518A patent/MY157745A/en unknown
- 2002-02-15 TW TW091102861A patent/TWI325319B/zh not_active IP Right Cessation
- 2002-02-18 PA PA20028540101A patent/PA8540101A1/es unknown
- 2002-02-26 PE PE2002000159A patent/PE20040175A1/es not_active Application Discontinuation
2003
- 2003-07-11 MA MA27235A patent/MA26152A1/fr unknown
- 2003-07-16 CR CR7023A patent/CR7023A/es unknown
- 2003-08-07 ZA ZA200306124A patent/ZA200306124B/xx unknown
- 2003-08-11 IL IL157341A patent/IL157341A/en not_active IP Right Cessation
- 2003-08-14 NO NO20033622A patent/NO20033622L/no not_active Application Discontinuation
2004
- 2004-02-03 US US10/770,656 patent/US20040157889A1/en not_active Abandoned
- 2004-02-03 US US10/770,655 patent/US20040157888A1/en not_active Abandoned
2005
- 2005-03-14 US US11/079,327 patent/US7230015B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/079,366 patent/US7179821B2/en not_active Expired - Lifetime
- 2005-09-27 US US11/236,145 patent/US7534803B2/en not_active Expired - Fee Related
2006
- 2006-01-05 HK HK06100186.8A patent/HK1080361B/zh not_active IP Right Cessation
- 2006-04-04 UA UAA200603708A patent/UA88773C2/ru unknown
2008
- 2008-03-13 AU AU2008201179A patent/AU2008201179B2/en not_active Ceased
2009
- 2009-04-06 JP JP2009091807A patent/JP2009185045A/ja not_active Abandoned
- 2009-04-29 US US12/420,390 patent/US20090281147A1/en not_active Abandoned
- 2009-04-29 US US12/420,416 patent/US20090209595A1/en not_active Abandoned
- 2009-04-29 US US12/420,407 patent/US20090209594A1/en not_active Abandoned
- 2009-04-29 US US12/420,381 patent/US20090270458A1/en not_active Abandoned
- 2009-11-19 AU AU2009238332A patent/AU2009238332A1/en not_active Abandoned
2010
- 2010-02-16 JP JP2010030929A patent/JP2010120958A/ja not_active Abandoned

Also Published As

Publication number	Publication date
NZ544720A (en)	2007-08-31
CR7023A (es)	2003-11-17
MY157745A (en)	2016-07-15
TR200800692T2 (tr)	2008-03-21
PA8540101A1 (es)	2003-09-05
HK1080361B (zh)	2009-10-30
MEP21208A (en)	2010-06-10
UA88773C2 (ru)	2009-11-25
KR20090005255A (ko)	2009-01-12
HRP20030652A2 (en)	2005-06-30
HUP0303203A3 (en)	2007-11-28
US20060025452A1 (en)	2006-02-02
EE200300363A (et)	2003-10-15
JP2010120958A (ja)	2010-06-03
NZ556697A (en)	2009-01-31
TR200800693T2 (tr)	2008-07-21
BR0207272A (pt)	2004-02-10
US20090281147A1 (en)	2009-11-12
HUP0303203A2 (hu)	2003-12-29
CZ20032172A3 (cs)	2004-01-14
CN1679564A (zh)	2005-10-12
ECSP024218A (es)	2003-09-24
KR100951540B1 (ko)	2010-04-09
US6967210B2 (en)	2005-11-22
WO2002064126A3 (fr)	2003-02-20
AU2002247200B9 (en)	2008-07-10
YU62903A (sh)	2006-05-25
KR20090005254A (ko)	2009-01-12
UA80394C2 (en)	2007-09-25
CO5390085A1 (es)	2004-04-30
JP2009185045A (ja)	2009-08-20
AR035750A1 (es)	2004-07-07
AP1749A (en)	2007-06-13
MXPA03006110A (es)	2005-07-01
CN1529598A (zh)	2004-09-15
AU2002247200B2 (en)	2007-12-13
HK1080361A1 (zh)	2006-04-28
US20090209594A1 (en)	2009-08-20
US20040157888A1 (en)	2004-08-12
US7534803B2 (en)	2009-05-19
NZ539159A (en)	2006-11-30
NO20033622D0 (no)	2003-08-14
KR20040014459A (ko)	2004-02-14
US20050159456A1 (en)	2005-07-21
AU2008201179A1 (en)	2008-04-03
OA12549A (en)	2006-06-05
NO20033622L (no)	2003-10-06
NZ527011A (en)	2005-07-29
CA2438712A1 (fr)	2002-08-22
SG134170A1 (en)	2007-08-29
EP1368031A2 (fr)	2003-12-10
US7179821B2 (en)	2007-02-20
TR200800691T2 (tr)	2008-03-21
PE20040175A1 (es)	2004-03-29
EA012409B1 (ru)	2009-10-30
PL363638A1 (en)	2004-11-29
JP2004518711A (ja)	2004-06-24
IL157341A0 (en)	2004-02-19
CN100522164C (zh)	2009-08-05
US20040157889A1 (en)	2004-08-12
US20050234105A1 (en)	2005-10-20
KR100951542B1 (ko)	2010-04-09
US20090270458A1 (en)	2009-10-29
AP2003002834A0 (en)	2003-09-30
US20090209595A1 (en)	2009-08-20
AU2009238332A1 (en)	2009-12-10
EA011319B1 (ru)	2009-02-27
EA200600896A1 (ru)	2006-08-25
WO2002064126A2 (fr)	2002-08-22
IL157341A (en)	2010-11-30
GB0119435D0 (en)	2001-10-03
TR200301330T2 (tr)	2004-12-21
US7230015B2 (en)	2007-06-12
SK10392003A3 (sk)	2004-01-08
TWI325319B (en)	2010-06-01
US20030105150A1 (en)	2003-06-05
EA200300882A1 (ru)	2003-12-25
ZA200306124B (en)	2004-11-08
AU2008201179B2 (en)	2009-08-20

Publication	Publication Date	Title
MA26152A1 (fr)	2004-07-01	Methode de traitement des maladies ou des cas de demyelinisation.
DE60124302D1 (de)	2006-12-14	Thiazolderivate zur behandlung von ppar-lierte krankheiten
MA26992A1 (fr)	2004-12-20	Derives de phenethanolamine pour le traitement des maladies respiratoires
ATE472325T1 (de)	2010-07-15	Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
FIU20060389U0 (fi)	2006-09-22	Luusairauksien hoito
ATE313540T1 (de)	2006-01-15	Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE414512T1 (de)	2008-12-15	Kombinationstherapie zur behandlung von krebs
PT1411926E (pt)	2005-10-31	Inibidores de integrina para o tratamento de doencas oftalmicas
DE60136477D1 (de)	2008-12-18	Retinoide zur behandlung von emphysem
DE60231107D1 (de)	2009-03-26	Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
EP1527196A4 (fr)	2007-03-14	Traitement de l'asthme ou des allergies
DE60236743D1 (de)	2010-07-29	Zur behandlung androgenabhängiger krankheiten
EP1611120A4 (fr)	2008-04-23	Nouvelles m thodes de traitement des maladies inflammatoires
EP1461027A4 (fr)	2005-09-07	Traitement de la neoplasie
EP1389105A4 (fr)	2005-08-17	Methode de traitement
EP1359885A4 (fr)	2005-03-16	Inhibiteurs de nos pour le traitement des rides
DE60016047D1 (de)	2004-12-23	Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
EP1441702A4 (fr)	2007-09-26	Methode de traitement de l'insomnie primaire
EP1282411A4 (fr)	2008-05-21	Methode de traitement anticancereux
DZ3225A1 (fr)	2001-05-10	Methode et compositions pour le traitement des maladies pulmonaires
DE60223707D1 (de)	2008-01-03	Calcium-l-threonat zur behandlung von knochenfrakturen
EP1553965A4 (fr)	2008-12-03	Methode de traitement des tumeurs
ATE409066T1 (de)	2008-10-15	Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
DE60005685D1 (de)	2003-11-06	Oxazinocarbazole zur behandlung von cns-erkrankungen
ATE343387T1 (de)	2006-11-15	S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.